Tony Pelz was a trader on a major European bank's proprietary trading desk, responsible for a portfolio with limits of more than $200 million. Prior to proprietary trading, Pelz worked with several global investment banks in roles ranging from corporate finance, M&A to credit and business development. He is author of The Biotech Trader Handbook, 2nd Edition, co-founder of the small-cap biotech research and trading site Chimera Research Group and operator of PelzOptions.com. Pelz currently resides in Denver, Colorado where he trades for his own account.
Recent Articles By The Author
Options Trade Into Ziopharm's Sarcoma Drug Study Results
Options expert Tony Pelz says options are the best way to trade Ziopharma's looming palifosamide data.
Dynavax Options Trade for Heplisav FDA Approval Decision
Options expert Tony Pelz offers investors a way to use options to trade Dynavax's upcoming FDA decision.
Alexza Pharma: Premium Selling Options Strategy
A new options trade for Alexza going into an FDA drug approval decision.
Amicus: Bullish Options Trade Into Clinical Trial Catalysts
Contributor Tony Pelz offers an options trade for those who believe Amicus shares are going higher.
Dynavax: Speculative Upside Options Trade
How to use options to play a possible run-up in Dynavax prior to the FDA's approval decision.